The pilot study on evaluation of zinc supplementation in patients with liver cirrhosis

The pilot study on evaluation of zinc supplementation in patients with liver cirrhosis - The evaluation of zinc supplementation in patients with liver cirrhosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036651

Enrollment

Registered

2019-05-05

Start date

2018-04-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis

Interventions

Administer 100 mg of zinc acetate hydrate (Nobelgin) daily for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) A patient with liver cirrhosis who is taking a BCAA preparation with a serum ammonia concentration of 80 micro-g / dL or more and a serum zinc concentration of 80 micro-g / dL or less. (2) Age at the time of consent is over 20 years old. (3) Written informed consent has been obtained from the applicant.

Exclusion criteria

Exclusion criteria: (1) Patients who do not meet selection criteria.

Design outcomes

Primary

Measure	Time frame
Transthyretin changes	—

Countries

Japan

Contacts

Public ContactHiroshi Tobita

Shimane University Hospital Department of Hepatology

ht1020@med.shimane-u.ac.jp0853-20-2190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026